(R)-Elagolix Size:Contact [email protected] for quotation InChi: InChI=1S/C35H54N4O9/c1-27(2)25-31(39-35(43)32(40)30(36)26-28-9-5-3-6-10-28)34(42)38-14-16-45-18-20-47-22-24-48-23-21-46-19-17-44-15-13-37-33(41)29-11-7-4-8-12-29/h3-12

InChi: InChI=1S/C35H54N4O9/c1-27(2)25-31(39-35(43)32(40)30(36)26-28-9-5-3-6-10-28)34(42)38-14-16-45-18-20-47-22-24-48-23-21-46-19-17-44-15-13-37-33(41)29-11-7-4-8-12-29/h3-12

Cinnamomum verum ingredient 2-methoxycinnamaldehyde: a new antiproliferative drug targeting topoisomerase I and II in human lung squamous cell carcinoma NCI-H520 cells

Combretastatin A-1 is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin

¹⁶]hexadeca-1(15)

25(12):1883-90

(R)-Elagolix Size:Contact [email protected] for quotation InChi: InChI=1S/C35H54N4O9/c1-27(2)25-31(39-35(43)32(40)30(36)26-28-9-5-3-6-10-28)34(42)38-14-16-45-18-20-47-22-24-48-23-21-46-19-17-44-15-13-37-33(41)29-11-7-4-8-12-29/h3-12Elagolix is a highly potent, selective, orally active, short duration, non peptide antagonist of the gonadotropin releasing hormone receptor (GnRHR) (KD = 54 pM). Target: GnRHin vitro: Elagolix is a short acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full